Tag Directory / PHARMACEUTICALS     showing 101–108 of 108


FDA rolls back warning labels on HRT products for menopause, citing misinformation / Fierce

fiercehealthcare - The action, announced Monday, follows a comprehensive review of scientific literature by an expert panel at the agency in July, as well as a public comment period, officials said. Pharmas are expected to update and reprint their product labeling to remove…

#healthcare #pharmaceuticals #publichealth #governmentpolicy

FDA Will Remove Warnings for HRT Products Used for Menopause

4 months / medcitynews / Marissa Plescia

FDA to remove boxed warnings from hormone therapy for menopause

4 months / beckershospitalreview / Ella Jeffries

The FDA removes a long-standing warning from hormone-based menopause drugs

4 months / medicalxpress

FDA seeks to remove warnings from labels of hormone therapies for menopause

4 months / endpoints / Zachary Brennan

FDA rolls back warning labels on HRT products for menopause, citing misinformation

4 months / fiercehealthcare

Monday, November 10, 2025, 5:24 pm / permalink 15854 / 5 stories in 4 months


Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera / MedCity

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer prevails in $10B bidding war for Metsera

4 months / beckershospitalreview / Ella Jeffries

Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firm

4 months / endpoints / Kyle LaHucik

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

4 months / medcitynews / Frank Vinluan

Novo Nordisk, Pfizer make personnel waves as they squabble over Metsera

4 months / endpoints / Alex Hoffman

Monday, November 10, 2025, 12:21 am / permalink 15823 / 4 stories in 4 months


Pfizer poised to buy Metsera in $10 bn deal after bidding war / Medical Express

medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer poised to buy Metsera in $10 bn deal after bidding war

4 months / medicalxpress

Novo Nordisk raises Metsera bid again, hoping to top Pfizer's latest offer

4 months / endpoints / Drew Armstrong

Saturday, November 8, 2025, 3:21 pm / permalink 15805 / 2 stories in 4 months


#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter / Endpoints

Elizabeth Cairns / endpoints - Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke. Repatha is already ...

#healthcare #pharmaceuticals #publichealth

Fat tissue around the heart may contribute to greater heart injury after a heart attack

2 months / medicalxpress

Uterine fibroids linked to elevated heart disease risk

3 months / medicalxpress

4 months / hcplive

4 months / hcplive

4 months / hcplive

4 months / hcplive

Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future

4 months / nytimes / Gina Kolata

Coronary artery calcium may be a predictor for all-cause mortality, including non-cardiac conditions

4 months / medicalxpress

Minimally invasive coronary calcium CT scans measuring heart disease risk can find other potential health problems

4 months / medicalxpress

4 months / hcplive

#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter

4 months / endpoints / Elizabeth Cairns

Avirup Guha: Leading Insights in Cardio-Oncology to be Presented at AHA25 in New Orleans

4 months / oncodaily

Avirup Guha: Key Cardio-Oncology Sessions at AHA25

4 months / oncodaily

Saturday, November 8, 2025, 9:21 am / permalink 15793 / 13 stories in 4 months


FDA approves J&J’s Darzalex for smoldering multiple myeloma / Endpoints

Lei Lei Wu / endpoints - The FDA on Thursday approved Johnson & Johnson’s Darzalex injection for high-risk smoldering multiple myeloma, a condition in which people have abnormal cells that could turn into myeloma but don’t have ...

#healthcare #pharmaceuticals #publichealth

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

4 months / oncodaily

4 months / targetedonc

FDA approves J&J’s Darzalex for smoldering multiple myeloma

4 months / endpoints / Lei Lei Wu

Saturday, November 8, 2025, 12:21 am / permalink 15786 / 3 stories in 4 months


Patient in Intellia CRISPR trial dies after being hospitalized with liver injury / Endpoints

Ryan Cross / endpoints - A man in his early 80s who was recently hospitalized with liver injury, a few weeks after receiving an experimental gene editing therapy, died on Wednesday ...

#healthcare #pharmaceuticals #publichealth

Intellia trial participant dies after severe liver reaction 

4 months / beckershospitalreview / Ella Jeffries

Patient in Intellia CRISPR trial dies after being hospitalized with liver injury

4 months / endpoints / Ryan Cross

Saturday, November 8, 2025, 12:21 am / permalink 15784 / 2 stories in 4 months


CMS unveils new Medicaid drug payment model / Endpoints

Max Bayer / endpoints - CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy

White House unveils MFN deals; Metsera saga ends; Q3 earnings updates; and more

4 months / endpoints / Max Gelman

CMS unveils new Medicaid drug payment model

4 months / endpoints / Max Bayer

CMS unveils new model to bring most-favored nation pricing to Medicaid

4 months / fiercehealthcare

Saturday, November 8, 2025, 12:21 am / permalink 15785 / 3 stories in 4 months


What Trump’s New Drug Pricing Deal Means for People With Obesity / NYT

Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

#trumpadministration #obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #governmentpolicy

Pfizer triumphs over Novo Nordisk with $10B bid for Metsera

4 months / endpoints / Elizabeth Cairns

Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

4 months / nytimes / Francesca Regalado

White House strikes new deals to lower prices on obesity drugs for some

4 months / npr / Sydney Lupkin

Trump Announces Deal to Drop Obesity Drug Prices to as Little as $149 a Month

4 months / nytimes / Rebecca Robbins, Margot Sanger-Katz and Dani Blum

What Trump’s New Drug Pricing Deal Means for People With Obesity

4 months / nytimes / Rebecca Robbins, Dani Blum and Margot Sanger-Katz

Eli Lilly, Novo Nordisk strike deals with White House to cut prices of weight loss drugs

4 months / fiercehealthcare

Friday, November 7, 2025, 11:57 pm / permalink 15780 / 6 stories in 4 months


Back to Top


PHARMACEUTICALS Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.